Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


28.01.2019

1 AJR Am J Roentgenol
1 Am J Clin Pathol
1 Ann Oncol
2 Ann Surg Oncol
6 BMC Cancer
2 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Auckl)
1 Breast Cancer (Dove Med Press)
5 Breast Cancer Res
9 Breast Cancer Res Treat
3 Breast J
1 Cancer
2 Cancer Lett
1 Carcinogenesis
3 Clin Breast Cancer
1 Clin Cancer Res
2 Int J Cancer
1 Int J Oncol
2 JAMA
1 Nature
5 NPJ Breast Cancer
2 Oncogene
1 Oncol Rep
1 Oncology
7 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. FUJII MH, Herschorn SD, Sowden M, Hotaling EL, et al
    Detection Rates for Benign and Malignant Diagnoses on Breast Cancer Screening With Digital Breast Tomosynthesis in a Statewide Mammography Registry Study.
    AJR Am J Roentgenol. 2019 Jan 23:1-6. doi: 10.2214/AJR.18.20255.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  2. SCHNEIDER F, Jin Y, Van Smaalen K, Gulbahce EH, et al
    The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers.
    Am J Clin Pathol. 2019 Jan 21. pii: 5298369. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Oncol

  3. DIECI MV, Conte P, Bisagni G, Brandes AA, et al
    Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Ann Oncol. 2019 Jan 17. pii: 5290085. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  4. SCHWARTZ TL, Margenthaler JA
    Value-Based Analysis for Breast Cancer Treatment: We Don't Know What We Don't Know.
    Ann Surg Oncol. 2019 Jan 23. pii: 10.1245/s10434-019-07170.
    PubMed     Text format    

  5. VAN LOEVEZIJN AA, van der Ploeg IMC
    ASO Author Reflections: A Reappraisal of Internal Mammary Chain Sentinel Node Biopsy in Breast Cancer Patients: Recommendations for Clinical Practice.
    Ann Surg Oncol. 2019 Jan 23. pii: 10.1245/s10434-019-07194.
    PubMed     Text format    


    BMC Cancer

  6. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Text format     Abstract available

  7. MIAH S, Bagu E, Goel R, Ogunbolude Y, et al
    Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
    BMC Cancer. 2019;19:78.
    PubMed     Text format     Abstract available

  8. KIM HK, Lee SH, Kim YJ, Park SE, et al
    Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    BMC Cancer. 2019;19:84.
    PubMed     Text format     Abstract available

  9. EBNER F, Wockel A, Schwentner L, Blettner M, et al
    Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
    BMC Cancer. 2019;19:90.
    PubMed     Text format     Abstract available

  10. KOTSAKIS A, Ardavanis A, Koumakis G, Samantas E, et al
    Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    BMC Cancer. 2019;19:88.
    PubMed     Text format     Abstract available

  11. ZHAO ZM, Yost SE, Hutchinson KE, Li SM, et al
    CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    BMC Cancer. 2019;19:96.
    PubMed     Text format     Abstract available


    Br J Cancer

  12. EGGEMANN H, Bernreiter AL, Reinisch M, Loibl S, et al
    Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0369.
    PubMed     Text format     Abstract available

  13. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Text format     Abstract available


    Breast Cancer

  14. BI Z, Liu J, Chen P, Liu Y, et al
    Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Breast Cancer. 2019 Jan 21. pii: 10.1007/s12282-018-00934.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  15. BUI TBV, Burgers DM, Agterof MJ, van de Garde EM, et al
    Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy.
    Breast Cancer (Auckl). 2019;13:1178223418823238.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  16. BUTTHONGKOMVONG K, Raunroadroong N, Sorrarichingchai S, Sangsaikae I, et al
    Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study.
    Breast Cancer (Dove Med Press). 2019;11:43-51.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  17. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2019;21:11.
    PubMed     Text format     Abstract available

  18. STRAND F, Azavedo E, Hellgren R, Humphreys K, et al
    Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study.
    Breast Cancer Res. 2019;21:8.
    PubMed     Text format     Abstract available

  19. CAMILIO KA, Wang MY, Mauseth B, Waagene S, et al
    Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Breast Cancer Res. 2019;21:9.
    PubMed     Text format     Abstract available

  20. JARMAN EJ, Ward C, Turnbull AK, Martinez-Perez C, et al
    HER2 regulates HIF-2alpha and drives an increased hypoxic response in breast cancer.
    Breast Cancer Res. 2019;21:10.
    PubMed     Text format     Abstract available

  21. LEHUEDE C, Li X, Dauvillier S, Vaysse C, et al
    Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
    Breast Cancer Res. 2019;21:7.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  22. EL-ANSARI R, Craze ML, Alfarsi L, Soria D, et al
    The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-018-05111.
    PubMed     Text format     Abstract available

  23. BATTISTI NML, Kingston B, King J, Denton A, et al
    Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Breast Cancer Res Treat. 2019 Jan 17. pii: 10.1007/s10549-019-05134.
    PubMed     Text format     Abstract available

  24. WEISS A, Grossmith S, Cutts D, Mikami SA, et al
    Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05116.
    PubMed     Text format     Abstract available

  25. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-019-05128.
    PubMed     Text format     Abstract available

  26. COOPEY SB, Kartal K, Li C, Yala A, et al
    Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05117.
    PubMed     Text format     Abstract available

  27. ROBERTSON S, Ronnlund C, de Boniface J, Hartman J, et al
    Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05119.
    PubMed     Text format     Abstract available

  28. PETRELLI F, Ghidini A, Pedersini R, Cabiddu M, et al
    Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-019-05133.
    PubMed     Text format     Abstract available

  29. XU X, Chlebowski RT, Shi J, Barac A, et al
    Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05086.
    PubMed     Text format     Abstract available

  30. CAMP NJ, Madsen MJ, Herranz J, Rodriguez-Lescure A, et al
    Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 23. pii: 10.1007/s10549-018-05097.
    PubMed     Text format     Abstract available


    Breast J

  31. KIM YJ, Shin HJ, Choi ME, Lee WJ, et al
    Radiation dermatitis with foreign body reaction clinically mimics a cutaneous metastasis from breast cancer.
    Breast J. 2019;25:141-142.
    PubMed     Text format    

  32. ABDULLAH N, O'Leary DP, Hegarty A, Albathali M, et al
    The effect of surgical site infection in immediate breast reconstruction on breast cancer recurrence.
    Breast J. 2019;25:166-168.
    PubMed     Text format    

  33. KLAR N, Brufsky A
    Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?
    Breast J. 2019;25:7-8.
    PubMed     Text format    


    Cancer

  34. PRINTZ C
    Black women less likely to adhere to hormone therapy for breast cancer.
    Cancer. 2019;125:331.
    PubMed     Text format    


    Cancer Lett

  35. YOON HJ, Kim DH, Kim SJ, Jang JH, et al
    Src-mediated phosphorylation, ubiquitination and degradation of Caveolin-1 promotes breast cancer cell stemness.
    Cancer Lett. 2019 Jan 20. pii: S0304-3835(19)30033.
    PubMed     Text format     Abstract available

  36. ZHANG K, Hong R, Kaping L, Xu F, et al
    CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
    Cancer Lett. 2019 Jan 21. pii: S0304-3835(19)30017.
    PubMed     Text format     Abstract available


    Carcinogenesis

  37. BANERJEE A, Birts CN, Darley M, Parker R, et al
    Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.
    Carcinogenesis. 2019 Jan 22. pii: 5292622. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  38. BLACKWELL KL, Zaman K, Qin S, Tkaczuk KHR, et al
    Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
    Clin Breast Cancer. 2018 Dec 20. pii: S1526-8209(18)30576.
    PubMed     Text format     Abstract available

  39. BLASCHKE SM, Gough KC, Chua BH, Francis PA, et al
    Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned.
    Clin Breast Cancer. 2018 Dec 21. pii: S1526-8209(18)30567.
    PubMed     Text format     Abstract available

  40. TANINI S, Fisher AD, Meattini I, Bianchi S, et al
    Testosterone and Breast Cancer in Transmen: Case Reports, Review of the Literature, and Clinical Observation.
    Clin Breast Cancer. 2018 Dec 20. pii: S1526-8209(18)30518.
    PubMed     Text format    


    Clin Cancer Res

  41. TULOTTA C, Lefley DV, Freeman K, Gregory WM, et al
    Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2202.
    PubMed     Text format     Abstract available


    Int J Cancer

  42. CADENAS C, Vosbeck S, Edlund K, Grgas K, et al
    LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32138.
    PubMed     Text format     Abstract available

  43. VARGA Z, Sinn P, Seidman AD
    Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score(R) (RS) assay and other genomic assays for early breast cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32139.
    PubMed     Text format     Abstract available


    Int J Oncol

  44. SELMIN OI, Donovan MG, Skovan B, Paine-Murieta GD, et al
    Arsenicinduced BRCA1 CpG promoter methylation is associated with the downregulation of ERalpha and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Int J Oncol. 2019 Jan 15. doi: 10.3892/ijo.2019.4687.
    PubMed     Text format     Abstract available


    JAMA

  45. WAKS AG, Winer EP
    Breast Cancer Treatment: A Review.
    JAMA. 2019;321:288-300.
    PubMed     Text format     Abstract available

  46. WAKS AG, Winer EP
    Breast Cancer Treatment.
    JAMA. 2019;321:316.
    PubMed     Text format    


    Nature

  47. NIK-ZAINAL S, Davies H, Staaf J, Ramakrishna M, et al
    Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
    Nature. 2019 Jan 18. pii: 10.1038/s41586-019-0883.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  48. JOHNSTON S, Martin M, Di Leo A, Im SA, et al
    MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
    NPJ Breast Cancer. 2019;5:5.
    PubMed     Text format     Abstract available

  49. PONDE N, Gelber RD, Piccart M
    PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
    NPJ Breast Cancer. 2019;5:1.
    PubMed     Text format    

  50. CONNOR AE, Visvanathan K, Boone SD, Rifai N, et al
    Fructosamine and diabetes as predictors of mortality among Hispanic and non-Hispanic white breast cancer survivors.
    NPJ Breast Cancer. 2019;5:3.
    PubMed     Text format     Abstract available

  51. ASKOXYLAKIS V, Ferraro GB, Badeaux M, Kodack DP, et al
    Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.
    NPJ Breast Cancer. 2019;5:4.
    PubMed     Text format     Abstract available

  52. BOUGHEY JC, Alvarado MD, Lancaster RB, Symmans WF, et al
    Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    NPJ Breast Cancer. 2019;5:2.
    PubMed     Text format     Abstract available


    Oncogene

  53. KIM I, Shin SH, Lee JE, Park JW, et al
    Oxygen sensor FIH inhibits HACE1-dependent ubiquitination of Rac1 to enhance metastatic potential in breast cancer cells.
    Oncogene. 2019 Jan 18. pii: 10.1038/s41388-019-0676.
    PubMed     Text format     Abstract available

  54. KOHLER M, Ehrenfeld S, Halbach S, Lauinger M, et al
    B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
    Oncogene. 2019 Jan 18. pii: 10.1038/s41388-018-0663.
    PubMed     Text format     Abstract available


    Oncol Rep

  55. FONTES-SOUSA M, Amorim M, Salta S, Palma De Sousa S, et al
    Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).
    Oncol Rep. 2019 Jan 11. doi: 10.3892/or.2019.6967.
    PubMed     Text format     Abstract available


    Oncology

  56. EIGELIENE N, Saarenheimo J, Jekunen A
    Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment.
    Oncology. 2019 Jan 17:1-10. doi: 10.1159/000495615.
    PubMed     Text format     Abstract available


    PLoS One

  57. KECHAVARZI BD, Wu H, Doman TN
    Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive genes in breast cancer samples from TCGA.
    PLoS One. 2019;14:e0210910.
    PubMed     Text format     Abstract available


  58. Retraction: Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKalpha-Mediated NF-kappaB Activation.
    PLoS One. 2019;14:e0207273.
    PubMed     Text format    

  59. SHOWALTER LE, Oechsle C, Ghimirey N, Steele C, et al
    Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib.
    PLoS One. 2019;14:e0210209.
    PubMed     Text format     Abstract available

  60. LAAS E, Hamy AS, Michel AS, Panchbhaya N, et al
    Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach.
    PLoS One. 2019;14:e0208807.
    PubMed     Text format     Abstract available

  61. VAN MAAREN MC, Kneepkens RF, Verbaan J, Huijgens PC, et al
    A conditional model predicting the 10-year annual extra mortality risk compared to the general population: a large population-based study in Dutch breast cancer patients.
    PLoS One. 2019;14:e0210887.
    PubMed     Text format     Abstract available

  62. CHATSIPROIOS D, Schmidts-Winkler IM, Konig L, Masur C, et al
    Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study.
    PLoS One. 2019;14:e0210967.
    PubMed     Text format     Abstract available

  63. ONISHI H, Udagawa C, Kubo M, Nakamura S, et al
    A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study.
    PLoS One. 2018;13:e0201606.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: